Durvalumab impacts progression-free survival while high-dose radiation > 66  Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)

Lung cancer is still the most prominent cause for cancer-related deaths worldwide [1]. The majority of patients are diagnosed with non-small cell lung cancer (NSCLC), 30  % of which present in locally advanced stage III [2]. Since the landmark publication by Antonia et al. the standard of care (SoC) for unresectable NSCLC stage III is concomitant chemoradiotherapy (cCRT) 60 – 66 Gy in 2 Gy fractions followed by Durvalumab for one year [3–6]. Although cCRT is preferably recommended by multiple prospective trials [7–11] and one meta-analysis [12], sequential regimens are still frequently used, especially in elderly patients and those deemed unfit for concomitant treatment [5–6].

Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Franz Zehentmayr, Petra Feurstein, Elvis Ruznic, Brigitte Langer, Brane Grambozov, Marisa Klebermass, Herbert H üpfel, Johann Feichtinger, Danijela Minasch, Martin Heilmann, Barbara Breitfelder, Claudia Steffal, Gisela Gastinger-Grass, Karoline Kirchhamm Tags: Original Article Source Type: research